Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

NCT01226420 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Discontinuation of drug supply from Astellas.

Conditions

Chronic Graft-versus-host Disease

Interventions

DRUG: Alefacept

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]